Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates

Shun Kawashima¹, Kole Joachim¹, Maen Abdelrahim², Ala Abudayyeh³, Kenar D. Jhaveri⁴,⁵, Naoka Murakami¹

¹Transplantation Research Center, Division of Renal Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
²Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer Center, Houston, TX, USA
³Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
⁴Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA
⁵Department of Internal Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA

Transplant care continues to advance with increasing clinical experience and improvements in immunosuppressive therapy. As the population ages and long-term survival improves, transplant patient care has become more complex due to comorbidities, frailty, and the increased prevalence of cancer posttransplantation. Immune checkpoint inhibitors (ICIs) have become a standard treatment option for many cancers in non-transplant patients, but the use of ICIs in transplant patients is challenging due to the possibility of disrupting immune tolerance. However, over the past few years, ICIs have gradually started to be used in transplant patients as well. In this study, we review the current use of ICIs after all solid organ transplantation procedures (kidney, liver, heart, and lung). Increasing data suggest that the type and number of immunosuppressants may affect the risk of rejection after immunotherapy. Immunotherapy for cancer in transplant patients may be a feasible option for selected patients; however, prospective trials in specific organ transplant recipients are needed.

Keywords: Immune checkpoint inhibitor; Transplantation; Graft rejection; Programmed cell death protein 1; Cytotoxic T-lymphocyte-associated protein 4

INTRODUCTION

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and increasingly become a standard of care for many cancer types. The binding of ICIs to either immune checkpoint molecules or their ligands inhibits the transmission of co-inhibitory signals, enabling T cell activation against cancer cells. Since the first Food and Drug Administration (FDA) approval in 2011, eight ICIs have been approved in the United States (US), and this number continues to grow [1]. It is currently estimated that 44% of newly diagnosed cancer patients are eligible for ICIs [2]. Solid-organ transplant (SOT) recipients were initially excluded from clinical trials of ICIs due to concerns for their safety, yielding little initial data for this patient population. The demonstrated efficacy of ICIs in non-transplant patients with cancer has motivated a gradual assessment of the efficacy and safety of ICI therapies in patients
Kawashima S et al. Immunotherapy for cancer in transplant patients

HIGHLIGHTS

- Immunotherapy for cancer in transplant patients is becoming more common, as immunotherapy has received Food and Drug Administration approval for more cancers.
- Immunotherapy for solid organ transplant recipients is challenging due to a higher risk of rejection.
- Prospective clinical studies investigating the optimal adjustment of immunosuppressants are awaited.

with SOT. Herein, we review the potential mechanisms of ICI-associated rejection of transplanted organs and the literature on reported cases where ICIs were used in transplant recipients, and we discuss the outcomes.

MECHANISMS OF ACTION OF IMMUNE CHECKPOINT INHIBITORS TOWARD TUMOR CELLS

Tumor immunity is elicited through the cancer immunity cycle. First, when cancer cells release tumor-associated neoantigens, antigen-presenting cells (APCs) recognize and uptake the antigens. APCs then present the captured antigens on major histocompatibility complex (MHC) class I and MHC class II to T cells, resulting in their activation. Activated T cells can kill cancer cells by specifically recognizing and infiltrating the tumor microenvironment through interactions with T cell receptors and MHC I-bound cognate antigens. Repetition of this cycle occurs through the release of additional tumor-associated neoantigens upon T cell-induced cancer cell death, resulting in an increased response amplitude.

Co-inhibitory molecules, such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1/2 (PD-L1/2) and lymphocyte activation gene 3 (LAG-3), play critical roles in modulating the cancer immunity cycle (Fig. 1A). When PD-1 on T cells binds to PD-L1 or PD-L2 on cancer cells or APCs, T cell activation is suppressed, causing immune escape of cancer cells. Anti-PD-1 antibodies bind to PD-1 on T cells and inhibit the binding of PD-1 to PD-L1/2, thereby blocking the transmission of inhibitory signals and restoring the anti-tumor effect. Anti-PD-L1 antibodies inhibit PD-1 interactions with T cells by binding to PD-L1 expressed on cancer and APCs.

As a result, inhibitory signaling to T cells is blocked, and T cell activation is maintained. Another ICI target includes cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is expressed on activated T cells and regulatory T cells (Tregs). CTLA-4 inhibits T cell activation by binding to B7 (CD80/CD86) on APCs. By inhibiting the binding of CTLA-4 to B7, the anti-CTLA-4 antibody enables the binding of CD28 (a co-stimulatory molecule on T cells) to B7, thereby reactivating T cells. Additionally, LAG-3 is a cell surface molecule expressed on effector T cells and Tregs. Inhibition of LAG-3 may restore the effector function of exhausted T cells and promote anti-tumor responses. In particular, it started to be clinically used in combination with anti-PD-1 antibodies (Fig. 1A) [3,4].

CURRENT INDICATIONS OF IMMUNE CHECKPOINT INHIBITORS AND RESPONSE RATE

The FDA approval of ipilimumab (2011), an anti-CTLA-4 antibody was followed by the emergence of anti-PD-1 antibodies, which include pembrolizumab (2014), nivolumab (2014), durvalumab (2017), avelumab (2017), cemiplimab (2018), and dostarlimab (2021). With the inclusion of atezolizumab, an anti-PD-L1 antibody, eight ICI therapies have been approved for use in the US. The number of cancer types that received FDA approval for ICIs continues to increase every year, from advanced melanoma in 2011 to 22 types of cancer at present[1,5].

In 2011, only 1.5% of cancer patients were eligible for ICIs in the US. However, ICIs are now indicated in more than 40% of cancer patients as of 2022. The percentage of patients estimated to respond to ICIs was 0.14% in 2011 and increased to 12.5% in 2018 [2]. According to global statistics from 2020, there were 19.3 million new cancer cases worldwide. Adapting this percentage, roughly 7.72 million people are eligible for ICIs each year, and 2.4 million people have the potential to benefit from ICIs [6].

POSTTRANSPLANT CANCER AND IMMUNE CHECKPOINT INHIBITORS: A LITERATURE REVIEW

Kidney, liver, heart, and lung transplants are the most commonly performed SOTs. Progress in surgical techniques and advances in immunosuppressants have
improved the survival of transplant recipients. As a result, the number of patients who develop cancer post-transplant is increasing over time. Importantly, the risk of cancer is much higher in transplant patients than in non-transplant patients due to their long-standing immunosuppressed state [7]. Suppression of the immune system against carcinogenic viruses and the inhibition of cancer immune surveillance can lead to the development of a variety of cancers. While most cancers post-transplant occur de novo after transplantation, rare causes of post-transplant cancer include the recurrence of (microscopic) cancer that was present in patients prior to transplantation or donor-derived cancer transmission [8-10]. Additionally, virus-associated cancers, most commonly caused by the Epstein-Barr virus and human herpes virus, frequently arise from the immunological suppression of many patients on allograft rejection prevention therapies. Vajdic et al. [11] reported that the standardized incidence ratio of cancer was 3.27 in post-kidney transplant patients compared to non-transplant patients. ICI use in transplant patients was first reported by Lipson et al. [12] in 2014. Since then, the number of case reports of ICI therapies in kidney and liver transplant recipients has gradually increased, and there are scattered case reports of ICI use in patients after heart and lung transplantation.
Mechanisms of ICI-Induced Rejection of Transplanted Organs
In transplant recipients, the donor cells release donor antigens and provoke an alloantigen-directed immune response. Immunosuppressants such as calcineurin inhibitors (CNIs), mycophenolate mofetil (MMF), mammalian target of rapamycin (mTOR) inhibitors, and steroids are the mainstay for suppressing T cell activation and regulating immunological tolerance. In patients with cancer after organ transplantation, the dose of immunosuppressants is often reduced to avoid over-immunosuppression and to recover adequate tumor immunity, based on their cancer type and severity. ICIs have the potential to disrupt the equilibrium of immunological tolerance and lead to acute rejection, with the frequency depending on the transplant organ type (Fig. 1B) [13].

Kidney Transplantation
Kidney transplant recipients survive for more than 15 years on average [14], and cancers associated with long-term immunosuppression are common. Although ICI use is undoubtedly challenging because of the increased risk of rejection, the largest number of ICI-treated cases was reported in kidney transplant recipients among all SOT recipients, because hemodialysis is available as a back-up therapy even if rejection occurs. The most commonly reported types of cancer are cutaneous squamous cell carcinoma (cSCC) and melanoma, and there are also reports of non-small cell lung cancer (NSCLC) and renal cell carcinoma (Table 1). Our group recently conducted the largest multi-center retrospective study to understand the safety and efficacy of ICIs in kidney transplant recipients. Out of 69 patients, 29 patients (42%) experienced rejection, of whom 19 patients (66%) developed allograft failure and needed dialysis. The use of an mTOR inhibitor, a three-immunosuppressant regimen, and deceased-donor kidney transplant status were associated with a lower risk of rejection [15]. Among a subgroup analysis of a cSCC cohort (n=47), both overall survival (OS) and disease-specific survival were slightly longer in patients receiving ICI therapies than in their non-ICI recipient counterparts. In an updated literature review, 96 cases with patient-level granular data were available, of whom 46 (48%) had acute allograft rejection and 33 (72%) needed dialysis. Thirty-two patients (34%) had tumor response to treatment (partial response [PR] or complete response [CR]) (Table 1). Interestingly, Lipson et al. [16,17] reported a successful kidney retransplantation for a patient who had lost an allograft after pembrolizumab therapy. The patient experienced severe allograft rejection 2 months after pembrolizumab therapy for cSCC. Nine months after the initiation of pembrolizumab, the patient achieved CR and pembrolizumab was discontinued. The patient maintained CR for 4.5 years and underwent a kidney retransplantation from an unrelated living donor, with one DR human leukocyte antigen mismatch. The patient received reduced thymoglobulin induction (3.0 mg/kg) and was maintained with CNI, MMF, and prednisone. The patient did not experience a rejection episode for more than 10 months post-retransplant at the time of the publication [16,17]. Pharmacovigilance studies have also reported a higher risk of allograft rejection based on Vigibase, the World Health Organization’s global database of reported potential side effects of medical products. Sixty-five cases of acute allograft rejection were associated with nivolumab (the information component 025; the lower limit of a 95% credibility interval for the information component (IC$_{025}$=1.32), pembrolizumab (IC$_{025}$=1.17) and ipilimumab (IC$_{025}$=0.33). According to these reports, biopsy-proven rejections were mostly T-cell-mediated, whereas antibody-mediated rejection was less common [18,19]. This pharmacovigilance study approach is useful for accumulating a larger number of cases, but we should be aware of an inherent reporting bias and a high level of missing data. Therefore, prospective studies with granular patient-level data will be key to understanding the precise risk factors and immune modulation strategy.

Donor-derived cell-free DNA (dd-cfDNA) has been established as a non-invasive biomarker to assess acute rejection after a kidney transplant. dd-cfDNA has also previously been reported to have the potential for utilization in the assessment of acute rejection in patients receiving ICI therapies posttransplant [20]. Hurkmans et al. [21] reported that after initiation of nivolumab treatment for cSCC after kidney transplant, dd-cfDNA increased to 23%, which coincided with renal function deterioration and biopsy-proven acute rejection of the allograft. In contrast, Lakhani et al. [22] reported that after 10 months of treatment with pembrolizumab for melanoma, dd-cfDNA increased slightly (<0.7%) from below the detection limit (<0.19%), but did not exceed the 1% threshold suggestive of acute rejection. These findings suggest that the treatment of melanoma with pembrolizumab can be successful without evidence of allograft dysfunction or rejection. While these findings are promising, further cases are expected to be accumulated to elucidate the utility and
| Study                        | Type of cancer | Allograft outcome | Checkpoint inhibitor | Year from tx to ICI | IS regimen | Cancer response | Interval between IS reduction and ICI initiation | ICI to rejection time |
|-----------------------------|----------------|-------------------|----------------------|---------------------|------------|-----------------|------------------------------------------------|-----------------------|
| Murakami et al. (2021) [15] | cSCC 24, Melanoma 22, NSCLC 8, MCC 4, RCC 3, Bladder Ca 2, Others 6 | Rejection in 29/69 (19HD) | Pembrolizumab 29, Nivolumab 11, Cemiplimab 10, Atezolizumab 3, Avelumab 3, Ipilimumab 2, Combination 11 | 9.33 (4.1–15.6) | Steroid, antemetabolite, mTORi, CNI, dynamic steroid+mTORi, etc. | CR 5, PR 15, SD 13, PD 34, NA 4 | NA |
| Lakhani et al. (2021) [22]  | cSCC           | No rejection      | Pembrolizumab        | 7                   | Tac 8 mg+MMF 1,000 mg+Pred 5 mg → everolimus+MMF 500 mg | SD          | 5 mo |
| Tan et al. (2021) [23]      | Melanoma       | Rejected, HD      | Nivolumab            | 14                  | Tac+MMF+Pred → Tac+Pred | CR          | 10 mo 15 day |
| Tsunget al. (2021) [24]     | cSCC           | No rejection      | Cemiplimab×12        | NA                  | Everolimus+Pred | PR          | NA |
|                           | cSCC           | No rejection      | Cemiplimab×2          | NA                  | Everolimus+Pred | PD          | NA |
|                           | cSCC           | Rejected, no HD   | Cemiplimab×7         | 14.3                | Tac+Pred    | SD          | NA 2 mo |
|                           | cSCC           | No rejection      | Cemiplimab×5         | NA                  | Everolimus+Pred | PR          | NA |
| Kumar et al. (2020) [25]    | facial SCC     | Rejected, reacted pulse | Pembrolizumab          | 15                  | Tac+MMF+Pred → sirolimus+MMF+Pred | CR          | NA 8 mo |
|                           | Melanoma       | Rejected, reacted pulse | Pembrolizumab          | 11                  | Tac+MMF+Pred → sirolimus+MMF | SD          | NA 1 mo |
| Trager et al. (2020) [26]   | Melanoma       | No rejection      | Ipilimumab and nivolumab then nivolumab | 3                  | Tac+sirolimus → sirolimus → off | PR          | 1 mo |
|                           | Melanoma       | Rejected, HD      | Pembrolizumab then ipilimumab+nivolumab | 2                  | Tac+MMF+Pred → Pred | PD          | 1 mo 1 mo |
|                           | cSCC           | No rejection      | Cemiplimab then ipilimumab and nivolumab | 13                 | Tac+sirolimus+MMF → sirolimus | PR          | 2 mo |
|                           | Melanoma       | Rejected, reacted pulse | Nivolumab and ipilimumab | 4                  | Sirolimus+MMF+Pred → sirolimus+Pred | SD          | 1 mo |
| Venkatachalam et al. (2020) [27] | cSCC       | Rejected, HD      | Pembrolizumab          | 3                  | Tac+Pred → everolimus+Pred | PD          | Concurrent 8 wk |
|                           | cSCC           | No rejection      | Pembrolizumab          | 22                 | CYA+MMF+Pred → CYA↓+Pred | PD          | 6 wk NA |
|                           | RCC            | AKI, no HD        | Nivolumab            | 2                  | Tac+MMF+Pred → Tac↓+Pred → everolimus+Pred | PD          | NA 6 wk |
|                           | Melanoma       | No rejection      | Pembrolizumab, then ipilimumab, then nivolumab | 19                 | CYA+azathioprine+Pred → sirolimus+Pred | PD          | 3 mo NA |
|                           | Melanoma       | Rejected, HD      | Ipilimumab, then pembrolizumab | 15                 | CYA+azathioprine+Pred → Pred | PR          | NA 3 wk |
|                           | LUAD           | No rejection      | Pembrolizumab          | 10                 | Tac+Pred → Pred | PD          | Concurrent NA |
| Hurkmans et al. (2019) [21] | Melanoma       | Rejected, HD      | Nivolumab×5            | 5                  | Tac+MMF → Pred 20 mg | PD          | 1 wk 12 day |
| Study                         | Type of cancer            | Allograft outcome | Checkpoint inhibitor | Year from tx to ICI | IS regimen | Cancer response | Interval between IS reduction and ICI initiation | ICI to rejection time |
|------------------------------|---------------------------|-------------------|----------------------|---------------------|------------|----------------|-----------------------------------------------|------------------------|
| Zehou et al. (2018) [28]     | Melanoma                  | No rejection      | Ipilimumab x4        | 2                   | Tac+MMF+Pred → everolimus+MMF+Pred | PD             | Just before                                    |                        |
|                              |                           |                   |                      |                     |            |                |                                               |                        |
|                              | Melanoma                  | No rejection      | Ipilimumab x4        | 7                   | Tac+MMF+Pred → sirolimus+Pred | PD             | 8 mo                                          |                        |
|                              |                           |                   |                      |                     |            |                |                                               |                        |
|                              | Melanoma                  | No rejection      | Ipilimumab x3 then nivolumab | 6            | Everolimus+azathioprine+Pred | PD             | NA                                           |                        |
|                              |                           |                   |                      |                     |            |                |                                               |                        |
|                              | Melanoma                  | No rejection      | Ipilimumab x4        | 1                   | Tac+everolimus+Pred → MMF+everolimus↑+Pred↑ | PD             | 1 mo                                          |                        |
|                              |                           |                   |                      |                     |            |                |                                               |                        |
|                              | Melanoma                  | Rejected, HD      | Ipilimumab x1        | 26                  | Everolimus+Pred → Pred | SD            | 1 mo                                          | 27 days                |
|                              |                           |                   |                      |                     |            |                |                                               |                        |
|                              | Melanoma                  | No rejection      | Ipilimumab x4        | 23                  | CYA+Pred → everolimus | PR            | 8 mo                                          |                        |
| Barnett et al. (2017) [29]   | Duodenum adenocarcinoma   | No rejection      | Nivolumab            | 6                   | Tac+MMF+Pred → sirolimus+Pred | SD             | 1 wk                                          |                        |
| Kittai et al. (2017) [30]    | cSCC                      | No rejection      | Nivolumab            | 14                  | Tac+MMF → sirolimus | SD            | NA                                           |                        |
| Kwatra et al. (2017) [31]    | Melanoma                  | Rejected, BSC     | Pembrolizumab x2     | 13                  | Tac+MMF → azathioprine 100 mg daily and everolimus 0.5 mg twice | PD             | 1.5 mo                                        |                        |
| Alhamad et al. (2016) [32]   | Melanoma                  | Rejected, HD      | Ipilimumab x4 then pembrolizumab | 15          | CYA+Pred → Pred | PD            | NA                                           | 3 Weeks after pembrolizumab initiation |
| Boils et al. (2016) [33]     | NSCLC                     | Rejected, HD      | Nivolumab x3         | 5                   | CYA+Pred → CYA (decreased)+Pred | NA            | 2 yr                                          | NA                     |
| Herz et al. (2016) [34]      | Melanoma                  | No rejection      | Ipilimumab x3        | 8                   | Tac+Pred | PD             | NA                                           |                        |
| Jose et al. (2016) [35]      | Melanoma                  | Rejected, HD      | Ipilimumab x2        | 16                  | Tac → Pred | NA            | NA                                           | 1 mo                   |
| Lipson et al. (2016) [11, 16, 17] | cSCC                      | Rejected, HD      | Pembrolizumab x2     | 25                  | Pred 5 mg | CR            | NA                                           | 2 mo                   |
| Ong et al. (2016) [36]       | Melanoma                  | Rejected, HD      | Nivolumab            | 12                  | Tac+MMF+Pred → Pred 10 mg | PR            | 2 mo                                          | 8 day                  |
| Spain et al. (2016) [37]     | Melanoma                  | Rejected, HD      | Ipilimumab x4 then nivolumab | 15          | Tac+Pred → Pred 5 mg | PR            | NA                                           | 8 Days after nivolumab initiation |
| Lipson et al. (2014) [12]    | Melanoma                  | No rejection      | Ipilimumab           | 11                  | Tac+Pred → Pred 5 mg | PR            | 6 wk                                          |                        |
| Lipson et al. (2014) [12]    | Melanoma                  | No rejection      | Ipilimumab           | 8                   | Tac+MMF+Pred → Pred 5 mg | PD            | 1 yr                                          |                        |

tx, transplantation; ICI, immune checkpoint inhibitor; IS, immunosuppressant; cSCC, cutaneous squamous cell carcinoma; NSCLC, non-small cell lung cancer; MCC, Merkel cell carcinoma; RCC, renal cell carcinoma; HD, hemodialysis; mTOR, mammalian target of rapamycin inhibitor; CNI, calcineurin inhibitor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not applicable; Tac, tacrolimus; MMF, mycophenolate mofetil; Pred, prednisone; CYA, cyclosporin A; AKI, acute kidney injury; LUAD, lung adenocarcinoma; BSC, best supportive care.
mechanistic behavior of dd-cfDNA in transplant rejection.

Liver Transplantation

The use of ICIs in liver transplant recipients has been reported mainly in cases of patients with melanoma and cSCC (Table 2). Particularly notable in liver transplantation is the use of ICIs in the treatment of hepatocellular carcinoma (HCC) prior to and subsequent to transplantation. The most common indication for liver transplantation was hepatitis C virus (HCV)-associated cirrhosis at many European and American centers [38,39]. With advances in antiviral agents, the proportion of individuals on the waiting list due to HCV has declined dramatically. Alcohol-associated liver disease and other/unknown diagnoses (often representing liver disease due to non-alcoholic steatohepatitis) are now the leading indications for liver transplant listing. Candidates with a primary diagnosis of HCC compose 10.9% of new waiting list registrations, which has nearly doubled over the past decade in the US [40]. The number of liver transplants for HCC is rapidly increasing, with more than 1,000 liver transplants for HCC performed in the US every year [41]. The indications for transplantation in patients with HCC are based on the Milan criteria, which have been modified to expand the indication metrics over the years [42].

In 2017, the FDA approved nivolumab as an adjunctive treatment for patients whose treatment with sorafenib was unsuccessful. This was followed by the approval of pembrolizumab. The objective response rate (ORR) of nivolumab in patients with advanced HCC previously treated with sorafenib was 15% (CR, 6%; PR, 9%) [43]. The OS was 15% (CR, 6%; PR, 9%), with a median OS of 28.6 months for the first line of treatment and 15.6 months for the second line [44]. The ORR of pembrolizumab was reported as 17% (CR, 1%; PR, 16%) [45]. The options of drug combination therapy for HCC have also expanded, with FDA approval of the combination therapy of ipilimumab and nivolumab for HCC in 2019 [46].

In a recent report, the combination of atezolizumab and bevacizumab prolonged overall and progression-free survival (PFS) compared to sorafenib in patients with unresectable HCC [47]. Moreover, the combination of durvalumab and tremelimumab also significantly improved OS in patients with advanced, unresectable HCC compared to patients who received sorafenib (HIMALAYA study; NCT03298451) [48]. Thus, the combination of ICIs, or ICIs and molecular-targeted therapies is becoming the mainstream for HCC treatment. Accordingly, there has been an increasing number of case reports of ICI use in patients experiencing posttransplant HCC recurrence. In addition, cases of ICI use before transplant registration and during the waiting period have been reported (Table 2).

Based on a review of the current literature, a total of 42 patients were reported, of which 22 cases were posttransplant and 20 were pretransplant. In the posttransplant cases, rejection was reported in five cases (22.7%). However, six patients (27.3%) showed response to treatment (PR or CR). Among the cases that had received ICI pretransplant, five patients (25.0%) had acute rejection relatively early posttransplant, whereas six patients (30.0%) had a response to treatment (PR or CR). The lower incidence of acute rejection caused by ICIs compared to kidney transplant recipients may be related to the inherent tolerogenicity of liver transplants [49]. Our review identified no cases in which immunotherapy was performed both pre- and posttransplant.

“Liquid biopsy” using circulating tumor DNA (ctDNA) has been demonstrated as an excellent method of minimal residual disease (MRD) surveillance of primary hepatic malignancies in patients who have undergone liver transplants for HCC. ctDNA measures and analyzes DNA fragments derived from tumors that are excreted into the bloodstream. ctDNA provides a non-invasive approach to tracking MRD without the need for repeated tissue biopsies [42]. Ono et al. [50] analyzed ctDNA in 46 patients with HCC, including liver transplant recipients, and found that the cumulative incidence of recurrence and extrahepatic metastasis in the ctDNA-positive group was statistically significantly worse than that in the ctDNA-negative group (P=0.0102 and P=0.0386, respectively). Multivariate analysis identified ctDNA (P=0.038) as an independent predictor of microscopic vascular invasion into the portal vein [50].

Observational studies are also underway to use ctDNA to identify MRD after liver transplant and to correlate the presence of ctDNA with the risk of recurrence [51,52]. Similarly, the usefulness of ctDNA in the setting of ICI therapy has also been reported. A study in which pembrolizumab was used in five different groups of patients with advanced solid tumors showed that both baseline and changes in ctDNA levels from baseline were correlated with OS and PFS [53]. A cohort of 48 patients with unresectable HCC who received atezolizumab and bevacizumab showed that higher baseline ctDNA levels were associated with a greater tumor burden and that dynamic
### Table 2. Liver transplantation cases

| Study                          | Type of cancer | Before/after | Allograft outcome | Checkpoint inhibitor | Year from tx to ICI | IS regimen | Cancer response | Interval between IS reduction and ICI initiation | ICI to rejection time |
|-------------------------------|----------------|--------------|-------------------|----------------------|---------------------|------------|----------------|-------------------------------------------------|-----------------------|
| Tsung et al. (2021) [24]      | cSCC           | After        | No rejection      | Cemiplimab×2         | NA                  | Tac 1 mg   | PD             | NA                                              | NA                    |
| Qiu et al. (2020) [55]        | HCC Rec        | After        | No rejection      | Camrelizumab         | 4                   | Tac → sirolimus | PR             | 2 yr                                             | NA                    |
| Zhuang et al. (2020) [56]     | HCC Rec        | After        | No rejection      | Nivolumab            | 2.7                 | Tac         | SD             | NA                                              | NA                    |
| Biondani et al. (2018) [57]   | LUSC           | After        | No rejection      | Nivolumab            | 13                  | Tac+MMF+Pred → Tac+everolimus+Pred | SD              | 4 yr                                             | NA                    |
| Tsung et al. (2021) [24]      | cSCC           | After        | No rejection      | Cemiplimab×12        | NA                  | Tac 0.5 mg  | NA             | NA                                              | NA                    |
| DeLeon et al. (2018) [58]     | HCC Rec        | After        | No rejection      | Pembrolizumab×2      | 5.5                 | Everolimus, MMF | CR             | NA                                              | NA                    |
| Qiu et al. (2020) [55]        | HCC Rec        | After        | No rejection      | Nivolumab×4          | 7.8                 | Sirolimus, MMF | PD             | NA                                              | NA                    |
| Zhuang et al. (2020) [56]     | HCC Rec        | After        | No rejection      | Nivolumab×5          | 3.7                 | Tac         | PD             | NA                                              | NA                    |
| Biondani et al. (2018) [57]   | LUSC           | After        | No rejection      | Nivolumab×2          | 1.2                 | Tac         | NA             | NA                                              | NA                    |
| Gassmann et al. (2018) [59]   | HCC            | After        | No rejection      | Nivolumab            | 3                   | Everolimus  | PD             | None                                            | 7 day                 |
| Gassmann et al. (2018) [59]   | HCC            | After        | No rejection      | Ipilimumab then pembrolizum | 5 | Tac+MMF+Pred → sirolimus+MMF | PR | 1 yr |
| Kuo et al. (2018) [60]        | HCC            | After        | Cellular rejection| Nivolumab            | 3                   | Tac/sirolimus | CR             | NA                                              | NA                    |
| Rammohan et al. (2018) [61]   | HCC            | After        | No rejection      | Pembrolizumab        | 3                   | Tac/sirolimus | CR             | NA                                              | NA                    |
| DeToni et al. (2017) [62]     | HCC Rec        | After        | No rejection      | Nivolumab×15         | 1                   | Tac         | SD             | NA                                              | NA                    |
| Friend et al. (2017) [63]     | HCC Rec        | After        | Cellular rejection| Nivolumab            | 4                   | Sirolimus 2 mg | NA             | 17 day                                           | NA                    |
| Friend et al. (2017) [63]     | HCC Rec        | After        | Cellular rejection| Nivolumab            | 3                   | Tac 4 mg     | NA             | 7 day                                           | NA                    |
| Schwartsman et al. (2017) [64]| Melanoma       | After        | No rejection      | Pembrolizumab        | 20                  | Tac          | CR             | NA                                              | NA                    |
| Varkaris et al. (2017) [65]   | HCC Rec        | After        | No rejection      | Pembrolizumab        | 8                   | Tac → 50% reduction dose | PD | NA |
| Morales et al. (2015) [66]    | Melanoma       | After        | No rejection      | Ipilimumab×4         | 8                   | Sirolimus 3 mg → 1 mg, MMF → off | PR | 3 mo |
| Ranganathan et al. (2015) [67]| Melanoma       | After        | No rejection      | Ipilimumab           | 8                   | Tac         | SD             | NA                                              | NA                    |
| Chen et al. (2021) [68]       | HCC            | Before       | Acute rejection   | Toripalimab×10       | Tac, methylprednisolone | PD | None | 10 hr |
| Dehghan et al. (2021) [69]    | HCC            | Before       | Acute rejection   | Nivolumab            | Tac, MMF, Pred      | Near CR     | None | POD 10 |
| Qiao et al. (2021) [70]       | HCC            | Before       | Rejection in 1/7  | Pembrolizumab or camrelizumab | Tac, MMF, methylprednisolone, Pred, etc. | PR in 71% | None | POD 12 in one case |
| Tabrizian et al. (2021) [71]  | HCC            | Before       | Rejection in 1/9  | Nivolumab            | Tac, MMF, Pred      | Near CR in 3/9 | None | NA |
| Nordness et al. (2020) [72]   | HCC            | Before       | Acute rejection   | Nivolumab            | Tac, MMF, Pred      | CR         | None | POD 5 |
| Schwacha-Epper et al. (2020) [73]| HCC            | Before       | No rejection      | Nivolumab            | NA                  | PR         | None | None |

Tx, transplantation; ICI, immune checkpoint inhibitor; IS, immunosuppressant; cSCC, cutaneous squamous cell carcinoma; NA, not applicable; Tac, tacrolimus; PD, progressive disease; HCC, hepatocellular carcinoma recurrence; Rec, recurrence; PR, partial response; SD, stable disease; LUSC, lung squamous cell carcinoma; MMF, mycophenolate mofetil; Pred, prednisone; CR, complete response; POD, postoperative day.
changes in ctDNA levels after treatment were associated with response. Patients with undetectable ctDNA after treatment had a longer PFS [54]. Based on these results, it is expected that ctDNA will also be introduced as an efficacy indicator for ICI used before and after liver transplantation for HCC. Similar to kidney transplant acute rejection, dd-cfDNA can also be used to evaluate allograft tolerance in liver transplant recipients [74,75]. Levitsky et al. [75] reported that the area under the curve of dd-cfDNA in the acute rejection group (n=57) compared to the normal function group (n=94) was as high as 0.95, and dd-cfDNA decreased alongside normalization after treatment for acute rejection. Therefore, dd-cfDNA may become a biomarker for evaluating rejection in liver transplant patients who receive ICI treatment.

**Heart Transplantation**

Studies on heart transplant recipients treated with ICIs remain limited. Rejection and myocarditis can be fatal, and therefore more caution is being taken with the administration of ICIs in this patient group. ICI-induced severe myocarditis in non-transplant patients is rare (0.09%) but can be associated with a high rate of mortality [76]. For heart transplant recipients, ICI treatments for melanoma, cSCC, and NSCLC have been reported (Table 3). The mortality attributed to ICI-associated myocarditis, as reported in the World Health Organization database, ranges from 36% to 67% [77]. Alemtuzumab (an anti-CD52 antibody) and abatacept (CTLA-4 immunoglobulin) might be effective for treating severe myocarditis. Both alemtuzumab and abatacept are potent immunosuppressants used in SOT. Alemtuzumab is a monoclonal antibody that binds to CD52, a protein present on the surface of immune cells, such as mature lymphocytes, monocytes, and macrophages, but not on hematopoietic stem cells. Abatacept competes for CD28 occupancy with B7 on APCs, thereby inhibiting the co-stimulatory signaling in T cells [78,79]. ICI-associated rejection is often much more severe than immune-related adverse events in non-transplant patients in general, but these potent immunosuppressants may be able to treat allograft injury caused by ICIs in post-heart transplant patients.

**Lung Transplantation**

The lung is one of the most immunogenic organs among all SOTs [80], and the recipient requires higher doses of immunosuppressants [81]. As survival improves, the number of patients who develop cancer has been increas-

![Table 3. Heart transplantation cases](https://doi.org/10.4285/kjt.22.0013)
ing, and potential ICI candidates exist in patients after lung transplants as well. ICI treatment for lung transplant recipients is the least reported among the various types of SOT. This is likely because, as with the heart, severe acute rejection of the lung allograft is directly linked to mortality. In the scope of our review, we found reports of one melanoma case and two cSCC cases treated with ICIs in lung transplant recipients (Table 4). Although acute rejection was not evident in any of the three patients, Tsung et al. [24] reported that the patient developed immune-mediated pneumonitis after two courses of cemiplimab but was discharged home and maintained CR. Daud et al. [82] reported that one of the patients had acute graft dysfunction and the other died within 1 year of ICI treatment due to chronic lung allograft dysfunction. They suggested that ICIs for lung transplant recipients have a higher risk of allograft rejection and/or dysfunction, but might provide therapeutic benefits for their cancer.

**RISK FACTORS AND MECHANISTIC INSIGHTS ON ICI-ASSOCIATED REJECTION**

**The Number of Immunosuppressants in Combination and Steroid Mini-Pulses**

Posttransplant cancer is often managed with the reduction or discontinuation of immunosuppressants [87]. Our multi-center study suggested that a higher number of immunosuppressants used in a given patient at the time of ICI initiation was associated with a lower risk of acute rejection. Meanwhile, the ORR to ICIs for both melanoma and cSCC did not differ when stratified by the number of immunosuppressants [15]. Peri-infusion prednisone mini-pulses (40–20 mg over 1–2 weeks, beginning the day of or prior to ICI infusion) followed by 10 mg of prednisone daily for maintenance have also been reported to be effective in the prevention of acute rejection [29,88].

**mTOR Inhibitors**

mTOR inhibitors have been shown to be effective in cancer prevention and treatment [89]. The TUMORAPA study [90] demonstrated that kidney transplant recipients with a history of cSCC who switched from CNI to sirolimus after the first diagnosis of cSCC had a significant reduction in the recurrence of skin cancer compared to the group that continued CNI. These findings indicate the benefit of mTOR inhibitors in the immune system and for cancer prevention.
control. In the multi-center study described above, the rejection-free graft survival and overall graft survival were both longer in mTOR inhibitor-treated patients than in non-mTOR inhibitor-treated patients with cSCC [15]. Several reports have suggested that mTOR inhibitors may be useful in reducing rejection and controlling cancer [29]. In our multi-center study evaluating ICIs in kidney transplant recipients with cancer, the use of mTOR inhibitors was associated with a lower risk of rejection in multivariate analyses [15]. One case report suggested that sirolimus treatment abated cytotoxic T cell numbers and eosinophilia, while a higher number of Treg cells in the peripheral blood was maintained [91].

Based on the above, Table 5 shows our suggestions on immunosuppression modifications for practical use.

### Table 5. Our recommended potential immunosuppression modifications for practical use

| Modification      | Detail                                                                 |
|-------------------|------------------------------------------------------------------------|
| Dynamic steroid regimen | Pred 40 mg daily for 3 days (starting from day 1), 20 mg for 3 days, then 10 mg for the rest of the cycle |
| mTORi conversion | mTORi with a target trough level of 4–6 ng/mL                           |

Pred, prednisone; mTORi, mammalian target of rapamycin inhibitor.

### Table 6. Ongoing clinical trials of immunotherapy for cancer in transplant patients

| Organ | Study title                                                                 | Registration          | Cancer                                                                 | Interventions                                      | Phase  | Start date   |
|-------|-----------------------------------------------------------------------------|-----------------------|-----------------------------------------------------------------------|----------------------------------------------------|--------|--------------|
| Kidney| Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study [93] | ANZCTR Registration No. ACTRN12617000741381 | cSCC, head & neck SCC, melanoma, MCC, NSCLC, urothelial cancer, colorectal cancer, breast cancer, etc. | Nivolumab                                          | I      | May 22, 2017 |
| Kidney| Tacrolimus, nivolumab, and ipilimumab in treating kidney transplant recipients with selected unresectable or metastatic cancers [94] | ClinicalTrials.gov Identifier NCT03816332 | Melanoma, MCC, BCC, cSCC | Tacrolimus, nivolumab, ipilimumab | I      | Feb 1, 2019  |
| Kidney| Cemiplimab in AlloSCT/SOT recipients with cSCC (CONTRAC) [94]              | ClinicalTrials.gov Identifier NCT0439062 | cSCC | Cemiplimab, everolimus, sirolimus, prednisone | I/II    | Jul 15, 2020 |
| Liver | Safety and efficacy of PD-1 inhibitors in patients with liver transplant [94] | ClinicalTrials.gov Identifier NCT03966209 | HCC | JS001 (PD-1 inhibitor) | I      | May 1, 2019  |
| Liver | Atezolizumab and bevacizumab before surgery for the treatment of resectable liver cancer | ClinicalTrials.gov Identifier NCT04721132 | HCC | Atezolizumab, bevacizumab | II     | Feb 10, 2021 |

ANZCTR, Australian New Zealand Clinical Trials Registry; cSCC, cutaneous squamous cell carcinoma; MCC, Merkel cell carcinoma; NSCLC, non-small cell lung cancer; BCC, basal cell carcinoma; AlloSCT, allogeneic stem cell transplant; SOT, solid-organ transplant; PD-1, programmed cell death protein 1; HCC, hepatocellular carcinoma recurrence.

**TOLERANCE**

Long-term transplant recipients are thought to have established immunological tolerance to some degree and often require fewer immunosuppressants. d’Izarny-Gargas et al. [92] reported that the risk of rejection by ICIs was significantly lower in patients who were more than 8 years posttransplant. They also showed that the use of at least one immunosuppressant in addition to steroids reduced the risk of rejection, while a previous history of rejection significantly increased the likelihood of rejection with ICI treatment.
**GENE EXPRESSION ANALYSIS OF ICI-ASSOCIATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS**

ICI-associated acute allograft rejection is histopathologically indistinguishable from other T cell-mediated rejection or acute tubulointerstitial nephritis. Our group recently studied the gene expression signature of kidney biopsies using the Nanostring platform, which enabled us to analyze ~700 immune-related target gene profiles. This study found that the expression level of IFI27, an interferon alpha-induced transcript, was higher in cases of T-cell-mediated rejection after ICI use in kidney allograft than in acute interstitial nephritis [95]. Thus biopsy-based measurement of IFI27 gene expression represents a potential biomarker for distinguishing these entities, and it is expected that a risk assessment based on a genetic diagnosis will be possible through biopsy before treatment.

**ONGOING CLINICAL TRIALS**

There are five ongoing clinical trials for ICI use in transplant patients: three for kidney and two for liver transplant patients. Table 6 provides an overview of the trials. The first one is "Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study" (ANZCTR registration number ACTRN12617000741381) [93]. This study investigates the safety and efficacy of nivolumab for all types of cancer in kidney transplant recipients. Participants receive nivolumab (3 mg/kg) intravenously every 2 weeks, and the study treatment will continue as long as there is a clinical benefit for up to 2 years. The second study is "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers" (NCT03816332), a prospective study comparing existing therapies with tacrolimus, nivolumab, and ipilimumab for treating kidney transplant recipients with advanced melanoma, Merkel cell carcinoma, basal cell carcinoma, and cSCC.

The third is "Cemiplimab in AlloSCT/SOT Recipients with CSCC (CONTRAC)" (NCT04339062), which evaluates the safety and efficacy of cemiplimab as a treatment for advanced cSCC in participants who have previously received a kidney transplant or an allogeneic hematopoietic stem cell transplant. Kidney transplant recipients receive the study treatment drug of cemiplimab along with everolimus, sirolimus, and/or prednisone to prevent kidney rejection. The fourth one is "Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant" (NCT03966209), which assesses the safety and efficacy of PD-1 inhibitors such as JS001 in patients with liver transplants. The eligible patients in this study have recurrent or metastatic HCC after liver transplantation and have previously been treated with sorafenib or other targeted therapy. A biopsy is needed to exclude patients with positive allograft PD-L1 expression [94].

The last one is "Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer" (NCT04721132), which is a phase II trial assessing the efficacy of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (hepatectomy or liver transplant). This will be the first international trial that evaluates the utility and safety of atezolizumab and bevacizumab as a bridging therapy to liver transplant for patients beyond the Milan criteria [96]. As the number of cases increases, more clinical studies are anticipated to be conducted to establish a safer and more effective way to use ICIs in transplant recipients.

**PATIENT PERSPECTIVES ON POSTTRANSPLANT CANCERS**

Cancer is a feared outcome for patients posttransplant. Interviews conducted with 14 post-kidney transplant recipients performed by Williams et al. [97] elucidated patients’ beliefs and attitudes towards posttransplant cancers; patients had limited awareness of posttransplant cancers, and even if they did, it was skin cancer-focused. Patients tended to prioritize their current health issues over cancer screening and prevention, although they felt fear of cancer development. In a larger survey of 1,808 patients posttransplant, the possibility of cancer after transplant was considered to be of critical importance by patients, caregivers, and health professionals [98]. Similarly, a high percentage of recipients have strong hopes for graft survival [99]. These studies highlight the importance of understanding patients’ and caregivers’ values, while demonstrating the necessity of a multi-disciplinary shared decision-making process for cancer treatment options among patients, caregivers, and clinicians. This is particularly important because ICI therapy is associated with a high risk of rejection, and the treatment risk versus
benefit may be perceived differently on a case-by-case basis. To help guide the difficult decision-making, it is crucial to find ways to make ICI treatment more effective and safer for treating transplant recipients with cancer.

**CONCLUSIONS**

ICI therapy for cancer in transplant patients is still challenging. However, the number of cases is gradually increasing, especially in kidney and liver transplant recipients. The patient populations that can benefit from ICI therapy are gradually becoming clear, depending on the length of time after transplant and the adjustment of immunosuppressants. Prospective studies to better understand the risk factors of rejection and therapeutic targets are underway.

**ACKNOWLEDGMENTS**

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Funding/Support
This study was partly supported in part by National Institute of Health, K08DK120868 to Naoka Murakami.

ORCID
Shun Kawashima https://orcid.org/0000-0003-0118-7981
Kole Joachim https://orcid.org/0000-0002-3584-6976
Maen Abdelrahim https://orcid.org/0000-0002-6631-5035
Ala Abudayyeh https://orcid.org/0000-0002-5813-6299
Kenar D. Jhaveri https://orcid.org/0000-0003-1578-0524
Naoka Murakami https://orcid.org/0000-0001-8168-5811

**Author Contributions**
Conceptualization: SK, NM. Data curation: SK. Funding acquisition: NM. Writing—original draft: SK, KJ, NM. Writing—review & editing: all authors.

**REFERENCES**

1. Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 2021;23:39.
2. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019;2:e192535.
3. Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer 2017;41:100-10.
4. Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, et al. Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front Immunol 2018;9:385.
5. Food and Drug Administration (FDA). Drugs@FDA: FDA-approved drugs [Internet]. Silver Spring, MA: FDA [cited 2022 Jan 25]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
7. Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med 2013;3:a015677.
8. Pavlakis M, Michaels MG, Tlusty S, Turgeon N, Vece G, Wolfe C, et al. Renal cell carcinoma suspected at time of organ donation 2008-2016: a report of the OPTN ad hoc Disease Transmission Advisory Committee Registry. Clin Transplant 2019;33:e13597.
9. Eccher A, Girolami I, Motter JD, Marletta S, Gambaro G, Momo RE, et al. Donor-transmitted cancer in kidney transplant recipients: a systematic review. J Nephrol 2020;33:1321-32.
10. Eccher A, Girolami I, Marletta S, Brunelli M, Carraro A, Montin U, et al. Donor-transmitted cancers in transplanted livers: analysis of clinical outcomes. Liver Transpl 2021;27:55-66.
11. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31.
12. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin
Kawashima S et al. Immunotherapy for cancer in transplant patients

Oncol 2014;32:e69-71.

13. De Bruyn P, Van Gestel D, Ost P, Kruse V, Brochez L, Van Vlierberge H, et al. Immune checkpoint blockade for organ transplant recipients with advanced cancer: how far can we go? Curr Opin Oncol 2019;31:54-64.

14. Hariharan S, Israni AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med 2021;385:729-43.

15. Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int 2021;100:196-205.

16. Lipson EJ, Naqvi FF, Loss MJ, Schollenberger MD, Pardoll DM, Moore J Jr, et al. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection. Am J Transplant 2020;20:2264-8.

17. Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016;374:896-8.

18. Nguyen LS, Ortuno S, Lebrun-Vignes B, Johnson DB, Moslehi JJ, Hertig A, et al. Transplant rejections associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review. Eur J Cancer 2021;148:36-47.

19. Saberianfar S, Nguyen LS, Manouchehri A, Lebrun-Vignes B, Moslehi JJ, Johnson DB, et al. Solid organ transplant rejection associated with immune-checkpoint inhibitors. Ann Oncol 2020;31:543-4.

20. Melancon JK, Baxter M, Casasola R. Acute renal transplant rejection following nivolumab therapy for metastatic melanoma. BMJ Case Rep 2021;14:e238037.

21. Herz S, Höfer T, Papapanagiotou M, Leyh JC, Meyenborg S, Schadendorf D, et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer 2016;67:66-72.

22. Jose A, Yiannoullou P, Bhutani S, Denley H, Morton M, Picton M, et al. Renal allograft failure after ipilimumab therapy for metastatic melanoma: a case report and review of the literature. Transplant Proc 2016;48:3137-41.
Fairhead T, Knoll G. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. J Immunother Cancer 2016;4:64.

37. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute enal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol 2016;27:1135-7.

38. Trotter JF. Liver transplantation around the world. Curr Opin Organ Transplant 2017;22:123-7.

39. Graziadei I, Zoller H, Fickert P, Schneeberger S, Finkenstedt A, Peck-Radosavljevic M, et al. Indications for liver transplantation in adults: recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr 2016;128:679-90.

40. Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, et al. OPTN/SRTR 2020 annual data report: liver. Am J Transplant 2022;22 Suppl 2:204-309.

41. Organ Procurement and Transplantation Network (OPTN). Build advanced [Internet]. Carville, LA: OPTN [cited 2022 Feb 1]. Available from: https://optn.transplant.hrsa.gov/data/view-data-reports/build-advanced.

42. Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Saharia A, McMillan R, et al. Transplant oncology: an evolving field in cancer care. Cancers (Basel) 2021;13:4911.

43. El-Khoueiry AB, Sangro B, You T, Croczenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.

44. Croczenzi TS, El-Khoueiry AB, You TC, Melero I, Sangro B, Kudo M, et al. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. J Clin Oncol 2017;35(15 suppl):4013.

45. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.

46. Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment. Gene Expr 2020;20:53-65.

47. Finn RS, Qin S, Ikeda M, Galle PR, Drueneux M, Kim TY, et al. Atezolizumab plus bevacizumab in inresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.

48. Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furse J, et al. Phase 3 randomized, open-label, multi-center study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol 2022;40(4 suppl):379.

49. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006;6:1774-80.

50. Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, et al. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy. Cell Mol Gastroenterol Hepatol 2015;1:516-34.

51. Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 2020;8:34.

52. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res 2017;23:5729-36.

53. Bratman SV, Yang SY, Iafolla MA, Liu Z, Hansen AR, Bedard PL, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 2020;1:873-81.

54. Hsu CH, Lu S, Abbas A, Guan Y, Zhu AX, Aleshin A, et al. Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2020;38(15 suppl):3531.

55. Qiu J, Tang W, Du C. Immune checkpoint inhibitors in patients with recurrent hepatocellular carcinoma after liver transplantation: a case report and literature review. Curr Cancer Drug Targets 2020;20:720-7.

56. Zhuang L, Mou HB, Yu LF, Zhu AX, Aleshin A, et al. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2020;19:91-3.

57. Biondani P, De Martin E, Samuel D. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient. Ann Oncol 2018;29:286-7.
58. DeLeon TT, Salomao MA, Aqel BA, Sonbol MB, Yoko-da RT, Ali AH, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol 2018;9:1054-62.

59. Gassmann D, Weller S, Mertens JC, Reiner CS, Vruyt B, Nägeli M, et al. Liver allograft failure after nivolumab treatment—a case report with systematic literature research. Transplant Direct 2018;4:e376.

60. Kuo JC, Lilly LB, Hogg D. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. Melanoma Res 2018;28:61-4.

61. Rammohan A, Reddy MS, Farouk M, Vargese J, Rela M. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet? Hepatology 2018;67:1166-8.

62. De Toni EN, Gerbes AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient. Gastroenterology 2017;152:1631-3.

63. Friend BD, Venick RS, McDiarmid SV, Zhou X, Naini B, Wang H, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer 2017;64:e26682.

64. Schwartsman G, Perez K, Sood G, Katkhuda R, Tawbi H. Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma. Ann Intern Med 2017;167:361-2.

65. Varkaris A, Lewis DW, Nugent FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma. Am J Gastroenterol 2017;112:1895-6.

66. Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer 2015;3:22.

67. Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother 2015;38:211.

68. Chen GH, Wang GB, Huang F, Qin R, Yu XJ, Wu RL, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol 2021;66:101386.

69. Dehghan Y, Schnickel GT, Hosseini M, Burgoyme AM, Ajmera VH, Morris GP, et al. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Clin J Gastroenterol 2021;14:1718-24.

70. Qiao ZY, Zhang ZJ, Lv ZC, Tong H, Xi ZF, WuHX, et al. Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review. Front Immunol 2021;12:653437.

71. Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant 2021;21:1979-80.

72. Nordness MF, Hamel S, Godfrey CM, Shi C, Johnson DB, Goff LW, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant 2020;20:879-83.

73. Schwartz-Eipper B, Mincuana I, Banz V, Dufour JF. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology 2020;72:1488-90.

74. Lewis D, Glehn-Ponsirenas R, Gubahce N, Hooey LJ, Chaffin JM, Miles J, et al. High levels of donor-derived cell-free DNA in a case of graft-versus-host-disease following liver transplantation. Am J Transplant 2022;22:973-6.

75. Levitsky J, Kandpal M, Guo K, Kleiboeker S, Sinha R, Abecassis M. Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients. Am J Transplant 2022;22:532-40.

76. Johnson DB, Balko JM, Compton ML, Chalkias S, Gormham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749-55.

77. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755-64.

78. Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med 2019;380:2375-6.

79. Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med 2019;380:2377-9.

80. Chambers DC, Perch M, Zuckermann A, Cherikh WS, Harhay MO, Hayes D Jr, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report - 2021; fo-
81. Ivulich S, Westall G, Dooley M, Snell G. The evolution of lung transplant immunosuppression. Drugs 2018; 78:965-82.

82. Daud A, Mehra MR, Siu A, Johnson MR, Perch M, Budev M, et al. Immune checkpoint inhibitors in heart or lung transplantation: early results from a registry initiative. J Heart Lung Transplant 2020;39:604-6.

83. Grant MJ, DeVito N, Salama AK. Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations. Melanoma Manag 2018;5:MMT10.

84. Owonikoko TK, Kumar M, Yang S, Kamphorst AO, Pillai RN, Akondy R, et al. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunol Immunother 2017;66:45-50.

85. Gastman BR, Ernstoff MS. Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient. Ann Oncol 2016;27:2304-5.

86. Qin R, Salama AK. Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus. Melanoma Manag 2015;2:311-4.

87. Wong G, Chapman JR. Cancers after renal transplantation. Transplant Rev (Orlando) 2008;22:141-9.

88. Danesh MJ, Mulvaney PM, Murakami N, Riella LV, Silk AW, Hanna GJ, et al. Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy. Cancer Immunol Immunother 2020;69:1937-41.

89. Xie J, Wang X, Proud CG. mTOR inhibitors in cancer therapy. F1000Res 2016;5(F1000 Faculty Rev):2078.

90. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012;367:329-39.

91. Howell M, Wong G, Rose J, Tong A, Craig JC, Howard K. Patient preferences for outcomes after kidney transplantation: a best-worst scaling survey. Transplantation 2017;101:2765-73.